U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has requested from NHS England, NICE and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) regarding pricing negotiations over the biotech's Orkambi lumacaftor/ivacaftor and other CF drugs if the three parties do not reach a reimbursement agreement by the end of the month.

While the House of Commons Health and Social Care Committee sent the letters Nov. 7, it announced the news Nov. 9...